Mycobacterium cell wall-DNA Complex - ProMetic Life Sciences

Drug Profile

Mycobacterium cell wall-DNA Complex - ProMetic Life Sciences

Alternative Names: EN3348; MCC; MCC/HA; MCNA; Mycobacterium Cell Wall-DNA Complex/hyaluronic acid; Mycobacterium phlei cell-wall - nucleic acid complex; Prostacidin; Urocidin

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bioniche Life Sciences
  • Developer Bioniche Life Sciences; Endo Pharmaceuticals; ProMetic Life Sciences
  • Class Antiandrogens; Antineoplastics; DNA
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Interleukin 12 stimulants; Interleukin 6 stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Bladder cancer
  • No development reported Cancer; Infections; Peritoneal cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Infections in Canada (Parenteral)
  • 31 Oct 2016 Telesta Therapeutics has been acquired and merged into ProMetic Life Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top